|
BioStem Technologies (OTC: BSEM) continues to separate itself as one of the most compelling high-growth stories in MedTech. In its Q3 2025 results, the company reported $10.5 million in revenue, $0.8 million in GAAP net income, and its seventh consecutive quarter of positive adjusted EBITDA at $2.7 million—a rare feat in the small-cap regenerative medicine space. With $27.2 million in cash and a vertically integrated, GMP-compliant manufacturing platform, BSEM has demonstrated both financial resilience and operational discipline despite pricing pressures and a shifting reimbursement landscape. Zacks Small Cap Research's $25.50 price target underscores the company's potential for significant valuation expansion. Driving this momentum is BioStem's clinically validated BioREtain® technology, supported by a Level 1 randomized trial showing a 53% wound-closure probability vs. 31% for standard of care in diabetic foot ulcers. With new market access through the VA, state Medicaid programs, and hospital/ASC channels—and a planned Nasdaq uplisting targeted for mid-2026—BioStem is expanding into high-value markets estimated at $300–$350 million. As healthcare spending grows and wound-care needs surge, BSEM appears well-positioned to capture accelerating demand and gain institutional visibility. Today's editorial pick for you 3 of the Best Residential REITs to Buy for 2026Posted On Nov 25, 2025 by Chris Markoch  The case for residential REITs is becoming hard to ignore. Homeownership may still be the American dream, but data shows that America is still a renter's nation. Table of ContentsAnd recent data indicates that’s not likely to change anytime soon. Renter households continue to grow faster than homeowner households. According to Barron's: "With house prices still high, mortgage rates stuck just under 7%, and plenty of economic uncertainty, consumers are once again seeing the virtues of renting. Over a third of respondents, 35%, told Fannie Mae in April that they would rent instead of buy if they had to move, the highest share since October and more than the long-term average of three in 10." Residential REITs aren’t going to beat the growth opportunities that growth investors can get from stocks that are part of the artificial intelligence (AI) trade. However, they can be a solid choice for income-oriented investors, particularly at at a time when interest rates are coming down, which makes short-term Treasury bills less appealing. In fact, REITs are required to pay a healthy percentage of their earnings to shareholders. That means the certainty of regular dividends. If you think that real estate investment trusts (REITs) may be right for you, here are three names to consider. Residential REITS #1: Mid-America Apartment CommunitiesWith a yield of just over 4.54%, Mid-America Apartment Communities (NYSE: MAA) is an attractive, oversold opportunity. The REIT focuses on apartment communities in the Southeast, Southwest and Mid-Atlantic regions of the U.S. MAA stock is down 13.5% in 2025. However, the stock has risen approximately 5% since its earnings report on October 30. At that time, the company reported strong operating results with 95.6% physical occupancy, a 4.5% increase in renewals, and net delinquency at just 0.3%, indicating resilient demand and collections. MAA also paid a dividend of $1.515 per share on October 31, July 31, April 30, and January 31. Its next dividend payment should come at the end of January 2026. Residential REITs #2: Camden Property TrustWith a yield of about 4%, Camden Property Trust (NYSE: CPT) is one of the largest publicly traded multifamily companies in the United States. The company is primarily engaged in the ownership, management, development, redevelopment, acquisition, and construction of multifamily apartment communities. It also owns and operates 177 properties. CPT stock is down about 9.8% in 2025. However, it’s up about 7% since October 31. Part of those gains is due to the company’s strong earnings report. In its most recent earnings report, the company's funds from operations of $1.67 was in-line. Revenue of $395.68 million, up 2.2% year over year, missed by $2.86 million. Camden Propery Trust has a high-yield dividend of 4.02%. It pays out $4.20 per share on an annual basis. The most recent dividend payment of $1.05 per share came on October 17, 2025. Residential REITs #3: AvalonBay CommunitiesWith a yield of 3.87%, AvalonBay Communities (NYSE: AVB) invests in apartments. It just declared a dividend of $1.75 per share, which will be paid on January 15 to shareholders of record as of December 31. AVB stock is down about 18% in 2025, but has climbed about 3% since November 1. That corresponds to its earnings report on October 30. At that time, the company lowered its full-year core FFO guidance by $0.14 to $11.25, reflecting weaker same-store NOI and implied year-over-year earnings growth of about 2.2%. Most recently, analysts at Barclays, Scotiabank, and Morgan Stanley raised their price targets on the AVB stock. Morgan Stanley raised its price target to $228 with an equal-weight rating on the stock. Scotibank raised its price target from $241 to $251. This message is a PAID ADVERTISEMENT for BioStem Technologies (OTC: BSEM) from Sideways Frequency, LLC. StockEarnings, Inc. has received a fixed fee of $7000 from Sideways Frequency, LLC for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between Nov 25, 2025 and Dec 01, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies (OTC: BSEM) or Sideways Frequency, LLC. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency, LLC and BioStem Technologies (OTC: BSEM). StockEarnings, Inc |
0 Response to "📈 This Rising MedTech Firm About to Leave Its OTC Days Behind?"
Post a Comment